Lipocine posts Q3 net loss of $3.2 million on $831,000 revenue
Lipocine Inc. reported a net loss of $7.3 million, or ($1.4) per diluted share, for the nine months ended September 30, 2025, compared to a net loss of $1.8 million, or ($0.3) per diluted share, for the same period in 2024. Revenue for the nine months ended September 30, 2025, was $0.8 million, down from $7.7 million in 2024, primarily due to lower license revenue. Royalty revenue from TLANDO sales increased to $0.3 million from $0.2 million in the prior year. General and administrative expenses decreased to $2.8 million from $4.1 million, mainly due to lower business development and legal fees. Research and development expenses were $5.9 million, down from $6.3 million, reflecting lower costs for the LPCN 1154 Phase 3 clinical study. Interest and investment income declined to $0.6 million from $0.9 million. Lipocine continues to develop LPCN 1154, an oral formulation of brexanolone for postpartum depression.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16843) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.